Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29994416 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| SCHEMBL2264859 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| SCHEMBL3655274 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| SCHEMBL31234233 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| Hydrochloric Acid SCHEMBL31656540 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| Hydrochloric Acid SCHEMBL22031566 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| Hydrochloric Acid SCHEMBL1953010 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| Hydrochloric Acid SCHEMBL1953011 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| Hydrochloric Acid SCHEMBL28668620 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| SCHEMBL3984986 | 0.90 | CHRNB2 (0.55) | CHRNB2CHRNA4HTR1ASLC6A2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115335050-B | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| CN-115335050-A | Compounds and compositions for treating skin conditions | 卡玛瑞制药有限公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-3452465-B1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2020-11-04 | — | — | EP | disclosed |
| EP-3452465-B1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2020-11-04 | — | — | EP | disclosed |
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | GENOSCIENCE PHARMA (FR) | 2020-03-03 | — | — | US | disclosed |
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2019-05-16 | — | — | US | disclosed |
| WO-2017191599-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2017-11-09 | — | — | WO | disclosed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | NQO2, RECQL, CCNO | CHRNB2 4576/4885CHRNA4 4438/4885HTR1A 2414/4885 |
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | NQO2, RECQL, CCNO | CHRNB2 4576/4885CHRNA4 4438/4885HTR1A 2414/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | CHRNB2 3742/4885CHRNA4 3773/4885HTR1A 2403/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | CHRNB2 1324/4885CHRNA4 1298/4885HTR1A 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.